Diabetes, a global health problem increasing worldwide. Major cause of morbidity and mortality in Korea is due to diabetes and its complications. The prevalence of diabetes has increased from 1.5% to 9.9% in the past 40 years. The prevalence of impaired fasting glucose also increased to about 20% in 2009. It has been estimated that the prevalence of diabetes will rise to 11.4% in 2030. The risk factors for diabetes in Korea are age, obesity, smoking, decreased physical activity, and stress. With increasing obesity, especially in childhood, and improved longevity, the prevalence of diabetes is expected to dramatically increase more than previously estimated. Therefore, public efforts to introduce healthy lifestyle changes and diabetic prevention programs are necessary to reduce the global epidemic of diabetes.
With the increase in insulin bio similar and due to its affordable price, the insulin usage has increased among the patients who are not able to control the blood glucose levels with the traditional oral drugs. Thus, the use of insulin is rising from time to time. Technological advancements in the Insulin delivery devices for safer and accurate use of medicines have studied, and these otherwise called as management devices. The management devices include disposable insulin pens, reusable insulin pens, insulin syringes, insulin pumps, and jet injectors.
For these management devices to be used effectively from time to time, there are devices which measure the blood glucose levels accurately, and these are called monitoring devices, which include blood glucose meter and continuous glucose meter.
Globally Asia-Pacific holds the second place in the diabetes device market (approximately 40%) after North America. Diabetes Device Market size in 2017 for the Asia-Pacific was USD 13 billion and, South Korea contributes to 2% of the market.
Abbott, Johnson & Johnson, Sanofi, NovoNordisk, Eli Lilly, Animas Corporation, Becton Dickenson, Arkray, Ascensia Diabetes care, Agamatrix, Life Scan, Cellnovo Ltd., Insulet Corporation, Medtronics, Inc., Ypsomed, and Roche and Tandem Diabetes Care.
2018: Glarzia Prefilled Pen to be launched in South Korea in 2018 by GC pharma.
Jan 2018: The latest glucose-sensing smart contact lens is in its testing stage in animals. The device is the latest attempt to develop a needle-less blood sugar monitor for diabetics.
Base year for estimation
2018 – 2023
Revenue in USD million and CAGR from 2018 – 2023
Revenue forecast and market dynamics
This report can be customized to meet the desired requirements. Please connect with our analyst, who will ensure that you get a report that suits your needs.
1.1 Scope of Study
1.2 Market Definition
1.3 Executive Summary
2. Research Methodology
2.1 Study Deliverables
2.2 Study Assumptions
2.3 Research Phases
3. Market Insights
3.1 Technology Trends
3.2 Industry Attractiveness - Porter's Five Forces Analysis
3.2.1 Bargaining Power of the Suppliers
3.2.2 Bargaining Power of the Consumers
3.2.3 Threat of New Entrants
3.2.4 Threat of Substitute Products and Services
3.2.5 Competitive Rivalry within the Industry
4. Market Dynamics
5. Market Segmentation and Analysis
5.1 Monitoring Device
5.1.1 Self Blood Glucose Monitoring
22.214.171.124 Blood Glucose Meters
126.96.36.199.1 Blood Glucose Meters, Revenue (2012-2023)
188.8.131.52.2 Blood Glucose Meters, Volume (2012-2023)
184.108.40.206 Blood Glucose Test strips
220.127.116.11.1 Blood Glucose Test strips, Revenue (2012-2023)
18.104.22.168.2 Blood Glucose Test strips, Volume (2012-2023)
22.214.171.124.1 Lancets, Revenue (2012-2023)
126.96.36.199.2 Lancets, Volume (2012-2023)
5.1.2 Continuous Blood Glucose Monitoring
188.8.131.52.1 Durables, Revenue (2012-2023)
184.108.40.206.2 Durables, Volume (2012-2023)
220.127.116.11.1 Sensors, Revenue (2012-2023)
18.104.22.168.2 Sensors, Volume (2012-2023)
5.2 Management Device
5.2.1 Insulin Pump
22.214.171.124 Insulin Pump Device
126.96.36.199.1 Insulin Pump Devices, Revenue (2012-2023)
188.8.131.52.2 Insulin Pump Devices, Volume (2012-2023)
184.108.40.206 Insulin Pump Reservoir
220.127.116.11.1 Insulin Pump Reservoirs, Revenue (2012-2023)
18.104.22.168.2 Insulin Pump Reservoirs, Volume (2012-2023)
22.214.171.124 Infusion Set
126.96.36.199.1 Infusion Sets, Revenue (2012-2023)
188.8.131.52.2 Infusion Sets, Volume (2012-2023)
184.108.40.206 Syringes, Revenue (2012-2023)
220.127.116.11 Syringes, Volume (2012-2023)
18.104.22.168 Cartridges, Revenue (2012-2023)
22.214.171.124 Cartridges, Volume (2012-2023)
5.2.4 Disposable Pens
126.96.36.199 Disposable Pens, Revenue (2012-2023)
188.8.131.52 Disposable Pens, Volume (2012-2023)
5.2.5 Jet Injectors
184.108.40.206 Jet Injectors, Revenue (2012-2023)
220.127.116.11 Jet Injectors, Volume (2012-2023)
6. Competitive Landscape
6.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
7. Key Player Profiles
7.1 Abbott Diabetes Care
7.3 Johnson & Johnson
7.5 Ascensia Diabetes Care
7.6 AgaMatrix, Inc.
7.11 Novo Nordisk
7.12 Becton Dickinson
7.13 Eli Lilly
7.14 Ypsomed Holding AG
* Each Company Profile include overview, Revenue, Product and services, SWOT, Recent Activities and strategic Analysis.